An aspirin a day? Aspirin use across a spectrum of risk: cardiovascular disease, cancers and bleeds

Bibliography

• Ajani UA, Ford ES, Greenland KJ, et al. Aspirin use among U.S. adults: behavioral risk factor surveillance system. Am J Prev Med 2006;30(1):74-7
   PubMed Web of Science ®Google Scholar
• Pignone M, Anderson GK, Binns K, et al. Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am J Prev Med 2007;32(5):403-7
   PubMed Web of Science ®Google Scholar
• Kolber M, Sharif N, Marceau R, Szafran O. Family practice patients' use of acetylsalicylic acid for cardiovascular disease prevention. Can Fam Physician 2013;59:55-61
   PubMedGoogle Scholar
• Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men. JAMA 2006;295:306-13
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-60
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86
   PubMed Web of Science ®Google Scholar
• Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med 2008;121:43-9
   PubMed Web of Science ®Google Scholar
• Kotsevaa K, Wooda D, De Backer G, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;16:121-37
   PubMedGoogle Scholar
• Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378:1231-43
   PubMed Web of Science ®Google Scholar
• Steering Committee for the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-35
   PubMedGoogle Scholar
• Peto R, Gray R, Collins R, et al. Randomized trial of prophylactic daily aspirin in British male doctors. BMJ 1988;296:313-16
   PubMed Web of Science ®Google Scholar
• Medical Research Council. Thrombosis Prevention Trial: randomized trial of low-intensity oral anti-coagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233-41
   PubMedGoogle Scholar
• Hansson L, Zanchetti A, Carruthers SG, et al. HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-62
   PubMed Web of Science ®Google Scholar
• Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2001;357:89-95
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304
   PubMed Web of Science ®Google Scholar
• Steering Committee for the Physicians' Health Study Research Group. Preliminary report: findings from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1988;318:262-4
   PubMedGoogle Scholar
• Bruno G, Biggeri A, Merletti F, et al. Low incidence of end stage renal disease and chronic renal failure in type 2 diabetics. Diabetes Care 2003;26:2353-8
   PubMed Web of Science ®Google Scholar
• De Berardis G, Sacco M, Strippoli GFM. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531
   PubMed Web of Science ®Google Scholar
• Lip GYH, Felmeden DC, Dwivedi G. Antiplatelet agents and anticoagulants for hypertension. Cochrane Database Syst Rev 2011;12:CD003186
   Google Scholar
• Raju N, Sobieraj-Teague M, Hirsh J, et al. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 2011;124:621-9
   PubMed Web of Science ®Google Scholar
• Seshasai SRK, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes, meta-analysis of randomized controlled trials. Arch Intern Med 2012;172(3):209-16
   PubMed Web of Science ®Google Scholar
• Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). European Heart J 2012;33:1635-701
   PubMed Web of Science ®Google Scholar
• Bell AD, Roussin A, Cartier R, et al. The use of antiplatelet therapy in the outpatient setting: canadian cardiovascular society guidelines. Can J Cardi 2011;27:S1-29
   PubMedGoogle Scholar
• Calonge N, Petitti DB, DeWitt TG, et al. For the United States Preventative Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009;150:396-404
   PubMed Web of Science ®Google Scholar
• De Berardis G, Lucisano G, D'Ettorre A, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA 2012;307(21):2286-94
   PubMed Web of Science ®Google Scholar
• Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease. antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest 2012;141(Suppl2):e637S-68S
   PubMedGoogle Scholar
• Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15-19
   PubMed Web of Science ®Google Scholar
• Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalizations for adverse drug events in older americans. N Engl J Med 2011;365:2002-12
   PubMed Web of Science ®Google Scholar
• Laine L. Review article: gastrointestinal bleeding with low-dose aspirin – what's the risk? Aliment Pharmacol Ther 2006;24:897-908
   PubMed Web of Science ®Google Scholar
• Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000;321:1183-7
   PubMed Web of Science ®Google Scholar
• McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006;119:624-38
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Wilson M, Elwin C, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741-50
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Fowkes FGR, Belch JFF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011;377:31-41
   PubMed Web of Science ®Google Scholar
• Strurmer T, Glynn RJ, Lee IM, et al. Aspirin use and colorectal cancer: post-trial follow-up data from the physicians' health study. Ann Int Med 1998;128:713-20
   PubMedGoogle Scholar
• Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer the women's health study: a randomized controlled trial. JAMA 2005;294:47-55
   PubMed Web of Science ®Google Scholar
• Cook NR, Lee I, Zhang SM, et al. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013;159:77-85
   PubMed Web of Science ®Google Scholar
• Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302(6):649-59
   PubMed Web of Science ®Google Scholar
• Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA. mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596-606
   PubMed Web of Science ®Google Scholar